Hemogenyx Pharmaceuticals Share Discussion Threads

[on target] 08/10/2019 15:33

This was referred to by Tullynessle's posts above.
It's some sort of consortium that includes Hemo's subsidiary Hemogenyx-Cell and Orgenesis's subsidiary MaSTherCell.

Possibly related to gaining grants from the Belgium government.

[scaramouche1941] 08/10/2019 15:25

hxxps://www.biowin.org/fr/company/hemogenyx-cell
Does anyone know what this is all about?

[purple11] 08/10/2019 10:39

getting close to major supports now.anyone wanting in should consider buying now not chasing the next spike then moaning for an age on the bbs before selling them about now.
just need a little common sense.

[johntopdog] 06/10/2019 23:53

Good spot...

Hopefully another RNS for that too.

Things look like they are moving along now

[tullynessle] 06/10/2019 20:54

The tweet account "NCP Wallonie" may contain information about Wallonia (Belgium), that may be useful in future research by BB participants.




NCP Wallonie
@NCPWallonie
Aide au montage de projets de recherche européens. Suit les programmes #H2020 #ERAnet et #JTIs. S'adresse aux acteurs wallons de la recherche.
Wavrencpwallonie.beJoined April 2012

[tullynessle] 06/10/2019 20:51

The tweet from BioWin mentions Hemogenyx-Cell.

Note: BioWin refers to "The Health Cluster of Wallonia (Belgium). Health biotechnology & Medical Technologies"





BioWin asbl
@BioWin_asbl

BioWin welcomes its 16 new members!

@OsborneClarke, Global Morpho Pharma, Tools4Patient, Hemogenyx-Cell, OUAT!
@LiveSciences, @Biocair, ACTAVIA, @OncoRadiomics, Alvalux Medical, @PolyPeptideGrp,
@MyCellHub, NLO, @TelixPharma, VILS, @AesculapeC and @Miracor_Medical!


================

BioWin asbl
@BioWin_asbl

The Health Cluster of Wallonia (Belgium). Health biotechnology & Medical Technologies

[davevt] 04/10/2019 11:06

All eerily quiet and the doctor, as usual trying to pump his stock with under the radar tweets, then deleting them 😂

[davevt] 01/10/2019 18:07

Ask Vlad to make up some news!

[volsung] 01/10/2019 13:50

Time for me to leave this one for pastures new. GLA

[idontflykathy] 23/9/2019 16:35

No trade an still stock down!!

[idontflykathy] 23/9/2019 15:52

Even their twitter and Dr. Vlad has been silent since few days!

[johntopdog] 23/9/2019 14:56

Update very much needed as there has been a complete lack of news of late

[quickdraw18] 23/9/2019 12:28

Are they on the 27th?

[tsmith2] 23/9/2019 07:52

Results and update sometime this week?

[purple11] 20/9/2019 20:10

all about net yesr for me gl

[purple11] 12/9/2019 07:20

Fantastic ppl working for us.top drawer.gl

[purple11] 12/9/2019 07:20

Fantastic ppl working for us.top drawer.gl

[purple11] 06/9/2019 23:29

Not rocket science

Yet

Nfx

[purple11] 31/8/2019 02:57

The Longer the Base the Higher to Space.gl

[volsung] 29/8/2019 23:05

I shudda bought IDE but thems the breaks

[purple11] 29/8/2019 23:05

In May 2018, Hemogenyx struck a development agreement with an unnamed multinational biopharmaceutical company regarding its CDX antibody (CDX Ab), the Group’s lead asset. The partner has initiated preliminary discussions regarding a potential licensing deal. If the partner chooses to in-license the CDX Ab product candidate, we expect the partner would finance and manage the development of the platform through clinical trials, which would significantly reduce the capital required for commercialisation.




"should the unnamed partner license the CDX Ab product we would expect the partner topay Hemogenyx a substantial upfront payment and thenfinance and manage the rest of the development of the programme.We would also expect Hemogenyx to secure significant future milestone and royalty payments on such an agreement."


Hemogenyx operates in an area of intense focus for industry. Therefore, we compiled a peer group of ex-UK development-stage companies which operate within similar treatment areas to Hemogenyx (i.e. treatment of blood cancers or alternate therapies for bone marrow transplants). The median-market capitalisation of the peer-group is £129.1m, over 10-fold higher than that of Hemogenyx (Table 1).
We then compared Hemogenyx to several AIM or LSE standard-listed drug developers at a preclinical stage (Table 2). As is demonstrated, Hemogenyx’s current market capitalisation is half that of the peer-group median of c.£17.2m. Given that the Company has multiple assets, each with collaboration agreements, we believe that this price discrepancy is unjustified and that Hemogenyx shares consequently have considerable upside potential

[purple11] 29/8/2019 21:08

xXTiPSXHEETSXx

[purple11] 29/8/2019 20:57

BUY HOLD ADD seize the chance to build your holding and wait.

12 22 43

[purple11] 29/8/2019 20:56

relax

stocks are marked down across the board atm incase you hadn't noticed .summer doldrums and the sept swooon gl